Pharmaceutical

Filter

Current filters:

None

Popular Filters

12 to 36 of 7177 results

FDA approves Ipsen's Somatuline for metastatic gastroentero pancreatic neuroendocrine tumors

FDA approves Ipsen's Somatuline for metastatic gastroentero pancreatic neuroendocrine tumors

17-12-2014

The US Food and Drug Administration has approved Somatuline Depot (lanreotide) injection 120mg, manufactured…

IpsenOncologyPharmaceuticalRegulationSomatulineUSA

Top 30 Pharmas spent $112 billion on R&D in 2013; report

Top 30 Pharmas spent $112 billion on R&D in 2013; report

17-12-2014

The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development…

FinancialGlobalGlobalDataJohnson & JohnsonNovartisPfizerPharmaceuticalPharmaceutical sciencesResearch

Janssen returns rights of IBD drug GLPG1205 to Galapagos

Janssen returns rights of IBD drug GLPG1205 to Galapagos

17-12-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen has returned the rights to…

GalapagosGastro-intestinalsJanssenJanssen PharmaceuticaLicensingPharmaceutical

Cyclacel shares fall as sapacitabine disappoints in Phase III acute myeloid leukemia trial

Cyclacel shares fall as sapacitabine disappoints in Phase III acute myeloid leukemia trial

17-12-2014

The announcement that Cyclacel Pharmaceuticals’ (Nasdaq: CYCC) Phase III trial of sapacitabine was…

CyclacelOncologyPharmaceuticalResearchsapacitabine

New drug price cuts demonstrate Australian PBS sustainability

New drug price cuts demonstrate Australian PBS sustainability

17-12-2014

In Australia, price cuts to over 100 Pharmaceutical Benefits Scheme (PBS)-listed medicines that will…

AustraliaAustralian PBSHealthcarePharmaceuticalPricing

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

17-12-2014

In final guidance published today, UK health cost watchdog the National Institute for Health and Care…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

Lightlake in deal with Adapt Pharma subsidiary

16-12-2014

UK biopharma firm Lightlake Therapeutics has entered into a license agreement with Adapt Pharma Operations,…

Adapt PharmaLicensingLightlake TherapeuticsNaloxoneNeurologicalPharmaceutical

Trade groups call for integrated life science strategy ahead of European Commission Work Program

Trade groups call for integrated life science strategy ahead of European Commission Work Program

16-12-2014

European research and generic/biosimilar industry associatins have called for an integrated life science…

Advocacy groupsCompetitivenessEuropePharmaceuticalRegulation

Novartis gains US FDA approval of Signifor for acromegaly

Novartis gains US FDA approval of Signifor for acromegaly

16-12-2014

The US Food and Drug Administration has approved Swiss pharma giant Novartis’ Signifor (pasireotide)…

NovartisPharmaceuticalRare diseasesRegulationSigniforUSA

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

16-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued new…

InlytaOncologyPfizerPharmaceuticalPricingRegulationUK

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

Added benefit of Eylea over Lucentis in DME not proven, says IQWiG

16-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has compared trial data on German…

BayerEyleaGermanyLucentisNovartisOphthalmicsPharmaceuticalPricingRegulationRoche

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

UK NICE partially backs Bayer’s Xofigo in preliminary assessment

15-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) have recommended…

BayerOncologyPharmaceuticalPricingRegulationUKXofigo

OPKO Health leaps on potential $570 million deal with Pfizer

OPKO Health leaps on potential $570 million deal with Pfizer

15-12-2014

US drugmaker OPKO Health saw its shares leap 13.8% in pre-market trading, when it revealed a licensing…

LicensingOPKO HealthPfizerPharmaceuticalRare diseasesUSA

Immune Pharmaceuticals appoints Daniel Kazado chairman of the board

Immune Pharmaceuticals appoints Daniel Kazado chairman of the board

15-12-2014

US-Israeli company Immune Pharmaceuticals has appointed Daniel Kazado chairman of the board, succeeding…

BoardroomImmune PharmaceuticalsIsraelPharmaceuticalUSA

Spain’s Supreme Court opines on Pfizer dual pricing contracts

Spain’s Supreme Court opines on Pfizer dual pricing contracts

15-12-2014

The Spanish Supreme Court has reviewed a ruling adopted by the Audiencia Nacional, itself annulling a…

EuropeLegalPfizerPharmaceuticalPricingSpain

Novartis' Cosentyx demonstrates superiority to Stelara in head-to-head psoriasis study

Novartis' Cosentyx demonstrates superiority to Stelara in head-to-head psoriasis study

15-12-2014

Swiss drug major Novartis announced that the Phase IIIb CLEAR study for Cosentyx (secukinumab) met its…

CosentyxDermatologicalsNovartisPharmaceuticalResearchSwitzerland

India’s National Pharmaceutical Pricing Authority caps price of 52 more drugs

India’s National Pharmaceutical Pricing Authority caps price of 52 more drugs

15-12-2014

The National Pharmaceutical Pricing Authority (NPPA) of India has issued a notice capping prices of 52…

BaxterGlaxoSmithKlineIndiaPharmaceuticalPricingRegulationWockhardt

ETH and University of Zurich launch new translational center

ETH and University of Zurich launch new translational center

15-12-2014

Switzerland’s ETH Zurich and the University of Zurich (UZH) are taking their long-standing partnership…

ETH ZurichFinancialPharmaceuticalResearchSwitzerland

Australian mid-year economic and fiscal outlook does not show cost increases for PBS

Australian mid-year economic and fiscal outlook does not show cost increases for PBS

15-12-2014

The Mid-Year Economic and Fiscal Outlook released by the Australian government did not indicate any cost…

AustraliaHealthcare in AustraliaMedicines AustraliaPharmaceuticalRegulation

FDA approves third indication for Lilly’s Cyramza

FDA approves third indication for Lilly’s Cyramza

13-12-2014

The US Food and Drug Administration on Friday expanded the approved use of pharma major Eli Lilly’s…

CyramzaEli LillyOncologyPharmaceuticalRegulationUSA

Bayer fails in Indian Nexavar patent appeal

Bayer fails in Indian Nexavar patent appeal

13-12-2014

German pharma major Bayer suffered a significant disappointment on Friday, when India’s Supreme Court…

BayerIndiaLegalNatco PharmaNexavarOncologyPatentsPharmaceutical

Sanofi Pasteur gains FDA approval of Fluzone Intradermal Quadrivalent for adults

Sanofi Pasteur gains FDA approval of Fluzone Intradermal Quadrivalent for adults

13-12-2014

French pharma major Sanofi’s vaccines division, Sanofi Pasteur, has received approval from the US Food…

Anti-viralsFluzonePharmaceuticalRegulationSanofiSanofi PasteurUSAVaccines

12 to 36 of 7177 results

Back to top